Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. reports developments tied to its PetMeds pet pharmacy platform, its PetCareRx business, and the sale of prescription and non-prescription pet medications, preventatives, health products, and supplies. The company serves pet owners through direct-to-consumer channels and has announced distribution partnerships that extend pet pharmacy offerings across retail and digital channels.
Recurring news themes include product assortments focused on pet wellness, fiscal results and financial reporting updates, Nasdaq listing-rule communications related to periodic filings, board and audit committee changes, shareholder rights plan actions, and responses to unsolicited acquisition proposals. Coverage also reflects the company's positioning as a national pet pharmacy and pet health products retailer.
PetMeds (Nasdaq: PETS) launched a new co-branded online pet pharmacy with Rural King, giving Rural King customers access to pet medications, prescription food, preventatives and other pet health products through a digital platform powered by PetMeds. The service is available via RuralKing.com banners, Rural King email and social channels, and a dedicated link at RuralKing.PetMeds.com.
This is PetMeds’ first large-scale white-label pharmacy program, leveraging its pharmacy infrastructure, licensed pharmacists and e-commerce capabilities to support Rural King’s retail and online customer base, with AutoShip options for recurring needs. Introductory promotions RKPAW25 and RKKING50 offer sitewide discounts, subject to terms and exclusions.
PetMed Express (Nasdaq:PETS) confirmed receipt of an unsolicited, non-binding and conditional proposal from SilverCape Investments to acquire all outstanding shares for $3.00 per share in cash. This follows a prior $4.00 per share proposal made on December 11, 2025.
The Board, advised by financial and legal advisors, will evaluate the latest proposal but has made no determination and cautions there is no assurance any transaction will occur. The Board is prepared to engage with SilverCape once it executes a customary nondisclosure agreement with a standstill and continues to consider any credible value-maximizing proposal while focusing on core operations and long-term stockholder value.
PetMeds (NASDAQ:PETS) reported fourth quarter and fiscal 2026 results for the period ended March 31, 2026.
Q4 net sales were $42.8M (down 15.6% YoY) with a net loss of $4.1M. Fiscal 2026 net sales were $179.0M (down 21.1%), with a net loss of $57.3M, driven largely by a $26.7M goodwill impairment and higher costs. Adjusted EBITDA was $(2.8)M in Q4 and $(15.4)M for the year. The company also evaluated but declined unsolicited cash acquisition proposals of $4.00–$4.25 per share and will continue as an independent public company.
PetMed Express (Nasdaq:PETS), doing business as PetMeds and parent of PetCareRx, will report Q4 and fiscal year 2026 results for the period ended March 31, 2026, on Tuesday, June 2, 2026 after market close.
A conference call and webcast follow at 4:30 PM ET.
PetMeds (Nasdaq: PETS) announced a strategic partnership with Rural King on April 22, 2026 to launch a white-label pet pharmacy across Rural King retail stores and digital channels.
PetMeds will supply pharmacy infrastructure, licensed pharmacists and e-commerce capabilities to expand access to prescription medications, preventatives and pet health products, targeting millions of Rural King customers in rural communities.
Cardone Ventures submitted an unsolicited, non-binding all-cash proposal to acquire PetMed Express (Nasdaq: PETS) for $4.25 per share, implying an equity value of approximately $89 million on December 16, 2025.
The proposal is not subject to a financing contingency and is led by Brandon Dawson, Natalie Dawson, and Grant Cardone. Cardone Ventures highlights operational experience including scaling its firm to about $225 million in revenue in five years and managing over $2 billion in assets under management; Grant Cardone is described as managing over $5 billion of assets.
The offer is non-binding and conditioned on customary due diligence, a definitive agreement, and required approvals, and there is no assurance a transaction will be completed.
PetMeds (Nasdaq: PETS) confirmed receipt on Dec 11, 2025 of an unsolicited, non-binding proposal from SilverCape Investments Limited to acquire all outstanding shares for $4.00 per share in cash. The offer is subject to due diligence and execution of a definitive agreement but is not conditioned on financing. SilverCape publicly disclosed the proposal in an amendment to its Schedule 13D filed with the SEC on Dec 11, 2025. The PetMeds board, with financial and legal advisers, will review the proposal consistent with its fiduciary duties. The company said this letter is not a formal offer capable of acceptance and stockholders need take no action at this time.
PetMeds (Nasdaq: PETS) unveiled its 2025 Holiday Collection on December 10, 2025: a curated assortment of wellness-focused gifts for pets and pet parents emphasizing health, safety, and everyday comfort.
The collection highlights grooming items, first-aid and screening tests (including an at-home cancer urine test and multiple DNA tests), toys, treats, cat monitoring devices, equine grooming and supplements, and natural pest-repellent collars. The Holiday Giftable Essentials Collection is available now at PetMeds.com with fast shipping and subscription options for select items.
PetMeds (Nasdaq: PETS) announced that its Board unanimously approved an amendment extending the company’s existing shareholder rights plan by one year, moving the expiration from December 2, 2025 to December 2, 2026. All other terms remain unchanged.
The Board said the extension is intended to protect shareholders while it believes the stock does not reflect the company’s inherent value and because of recent significant accumulations of company common stock by certain shareholders. The Rights Plan is intended to ensure fair treatment and to guard against acquisitions without payment of an appropriate control premium. A Form 8-K will provide further details.
PetMed Express (Nasdaq: PETS) announced preliminary fiscal Q2 2026 results and filed a Form 12b-25 notifying the SEC of a late 10-Q filing for the quarter ended September 30, 2025. The Company estimates Q2 net sales of $43.4M–$44.5M versus $58.0M in the prior year and six-month net sales of $94.5M–$95.6M versus $124.3M prior. The company reported $36.1M cash and no debt as of September 30, 2025.
The Company cannot yet estimate operating or net income while it analyzes the timing and amount of an anticipated goodwill impairment. Nasdaq sent a notice of non-compliance; the company must update its plan by November 28, 2025, and any Nasdaq exception may be limited to December 29, 2025. The notice does not have an immediate effect on the stock listing.